Description
Book SynopsisTable of ContentsPart One Introduction Ch 1 Evolution of HCT, past, present, and future Ch 2 Human leukocyte antigen Ch 3 Introduction and basic science of chimeric antigen receptor therapies Ch 4 Statistical methods in HCT and cellular therapies Part Two Methodology Ch 5 Hematopoietic cell collection; bone marrow harvesting, apheresis, UCB Ch 6 Leukapheresis and manufacturing of CAR cells Part Three General Clinical Aspects Ch 7 Patient and donor selection and preparing for HCT Ch 8 General management of patients undergoing HCT Ch 9 Haploidentical HCT Ch 10 Umbilical cord blood transplantation Ch 11 Process and general management of patients undergoing CAR therapies Part Four Pharmacology and Radiation Therapy Ch 12 Preparative regimens used in HCT and CAR therapies Ch 13 Pharmacology of drugs used in HCT and CAR therapies Ch 14 Role of radiation therapy in HCT and CAR therapies Part Five Disease-Specific Indications and Results Ch 15 HCT in AML Ch 16 CAR therapy in AML Ch 17 HCT in ALL Ch 18 CAR therapy in ALL Ch 19 HCT in chronic leukemias; CML and CLL Ch 20 HCT in MDS Ch 21 HCT in myeloproliferative disorders Ch 22 HCT in aplastic anemia Ch 23 HCT in multiple myeloma Ch 24 CAR therapy in multiple myeloma Ch 25 HCT in light-chain amyloidosis Ch 26 HCT in NHL Ch 27 HCT in Hodgkin lymphoma Ch 28 CAR therapy in lymphoma Ch 29 HCT in rare malignancies Ch 30 HCT for hematologic malignancies in HIV patients Ch 31 HCT in solid tumors Part Six Prevention and Management of Complications Ch 32 Infectious complications Ch 33 Graft failure Ch 34 Graft-versus-host disease Ch 35 Miscellaneous complications of HCT Ch 36 Cytokine release syndrome Ch 37 Neurologic complications of CAR therapy (ICANS) Ch 38 Miscellaneous complications of CAR therapy Ch 39 Symptoms management and palliative care Ch 40 Survivorship
